Researchers studied genetically modified mice that lack NP2 itch-sensing neurons, to investigate the connection between itch, ...

Dazukibart, a type I interferon inhibitor, reduced dermatomyositis disease severity while maintaining a well-tolerated safety ...

Please provide your email address to receive an email when new articles are posted on . Phase 2a interim data show 100% of patients achieving the primary endpoint of skin toxicity improvement.

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose-limiting toxicity, today announced that it has secured a $30 million ...

Talimogene laherparepvec (T-VEC) demonstrates efficacy in cutaneous BCC, enhancing resectability and altering immune cell ...

Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, ...

Most immune cells express the receptors for epinephrine ... is characterized by elevated serum levels of allergen-specific IgE, cutaneous inflammation with infiltration of eosinophils, and ...

Dermatomyositis is a chronic systemic autoimmune disease characterized by cutaneous eruptions ... blocking its receptor-mediated signalling. Prior phase I data showed an acceptable safety and ...

Opens in a new tab or window Early in 2024, we reported on the FDA's call for new boxed warnings on the labeling of all approved chimeric antigen receptor ... and cutaneous TCL) started developing ...

The global market for oncology drugs was valued at US$231.56 billion last year and is projected to soar to US$532.91 billion by 2031, according to Coherent (NYSE: COHR) Market Insights.

umich.edu Clinical examination of joint position sense and vibration sense can provide important information concerning specific cutaneous sensory receptors, peripheral nerves, dorsal roots, and ...

Significant improvements in skin toxicity were observed by week 6 in all patients treated with HT-001 in the phase 2a ...